Asset Details
Do you wish to reserve the book?
Sanglifehrin A mitigates multiorgan fibrosis by targeting the collagen chaperone cyclophilin B
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sanglifehrin A mitigates multiorgan fibrosis by targeting the collagen chaperone cyclophilin B
Do you wish to request the book?
Sanglifehrin A mitigates multiorgan fibrosis by targeting the collagen chaperone cyclophilin B
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sanglifehrin A mitigates multiorgan fibrosis by targeting the collagen chaperone cyclophilin B
2024
Overview
Pathological deposition and crosslinking of collagen type I by activated myofibroblasts drives progressive tissue fibrosis. Therapies that inhibit collagen synthesis have potential as antifibrotic agents. We identify the collagen chaperone cyclophilin B as a major cellular target of the natural product sanglifehrin A (SfA) using photoaffinity labeling and chemical proteomics. Mechanistically, SfA inhibits and induces the secretion of cyclophilin B from the endoplasmic reticulum (ER) and prevents TGF-β1-activated myofibroblasts from synthesizing and secreting collagen type I in vitro, without inducing ER stress or affecting collagen type I mRNA transcription, myofibroblast migration, contractility, or TGF-β1 signaling. In vivo, SfA induced cyclophilin B secretion in preclinical models of fibrosis, thereby inhibiting collagen synthesis from fibrotic fibroblasts and mitigating the development of lung and skin fibrosis in mice. Ex vivo, SfA induces cyclophilin B secretion and inhibits collagen type I secretion from fibrotic human lung fibroblasts and samples from patients with idiopathic pulmonary fibrosis (IPF). Taken together, we provide chemical, molecular, functional, and translational evidence for demonstrating direct antifibrotic activities of SfA in preclinical and human ex vivo fibrotic models. Our results identify the cellular target of SfA, the collagen chaperone cyclophilin B, as a mechanistic target for the treatment of organ fibrosis.
Publisher
American Society for Clinical Investigation,American Society for Clinical investigation
Subject
/ Collagen
/ Collagen Type I - metabolism
/ Cyclophilins - antagonists & inhibitors
/ Endoplasmic Reticulum - drug effects
/ Endoplasmic Reticulum - metabolism
/ Fibrosis
/ Humans
/ Idiopathic Pulmonary Fibrosis - drug therapy
/ Idiopathic Pulmonary Fibrosis - metabolism
/ Idiopathic Pulmonary Fibrosis - pathology
/ Labeling
/ Lactones
/ Male
/ Mice
/ Myofibroblasts - drug effects
/ Proteins
